The global Rare Hemophilia Factors Market size is anticipated to reach USD 336.3 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.1% during the forecast period. Several factor concentrates gaining marketing approvals from regulatory bodies such as the U.S. FDA are expected to provide a significant push to the market. In addition, growing adoption of prophylaxis treatment by patients is expected to boost the growth of the market in coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life.
Favorable government initiatives and mandates to
increase diagnosis and treatment rates are escalating the growth of the market.
For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From
1983 to 2015, around 3,647 drugs were designated the status of orphan drugs and
554 drugs were approved by the U.S. FDA. Several key market players in the
market are focusing on R&D to launch new products and solutions for the
treatment of rare hemophilia factor disorders. For instance, in October 2015,
FDA approved Coagadex for treatment of hereditary factor X deficiency.
Introduction of new factor concentrates is likely to bolster market growth over
the forecast period.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/rare-hemophilia-factors-market
Further key findings from the
study suggest:
- Based
on type, factor VII accounted for the largest share in 2016, owing to higher
prevalence of this deficiency
- Factor
concentrates is anticipated to be the most promising segment, registering
a CAGR of 5.7% over the forecast period. This type of treatment is
considered to be the safest and most effective treatment for rare hemophilia
factor disorders
- Fresh
frozen plasma is estimated to command just over 53.0% of the market value
by 2025
- Asia
Pacific rare hemophilia factors market is expected to exhibit the highest
CAGR of over 5.5% during the same period. The growth of the region can be
attributed to wide base of population and high number of consanguineous
marriage
- Some
of the key players in the market are Novo Nordisk; Biogen; Bayer
healthcare; Pfizer, Inc.; Baxalta; CSL Behring; and Bio Products
Laboratory Ltd.
About Us:
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment